INSTITUTO DE SALUD CARLOS III SPANISH CELL THERAPY NETWORK December 14th, 2012

Business viability of a scientific project Solving the specific challenges of biotech & medtech products in order to attract investors.

Confidential 2

Credentials

3

€30 mn

>30

$300 mn

NEW THERAPIES LAUNCHED GLOBALLY.

VENTURE CAPITAL RAISED.

INTERNATIONAL LICENSING AGREEMENTS.

INNOVATIVE TECHNOLOGIES ANALYZED

USA, GERMANY, UK.

VENTURE CAPITAL “EARLY STAGE”.

PHARMA, BIOTECH & MEDTECH. 10 years

2 years

5 years

Confidential 3

Index

1. Intro

2. The WRAPUP© methodology of analysis

3. Summary

Confidential 4

Early considerations

Confidential 5

BENEFIT

RISK

TIME

Intro

Confidential 6

TEAM

PRODUCT / TECHNOLOGY

EXIT

FINANCING

Intro

1. The WRAPUP© methodology of analysis

Confidential 8

The WRAPUP© methodology of analysis

Relevant

Unique

Protectable Achievable

Profitable

Is there a real unmet need for your tech today?

Will it stay competitive in the future?

Can it be protected from copyists? What risks & barriers may prevent success?

What How profitable and cashable is it?

Confidential 9

1. What

What will you sale?

Hospital

Physician

How will you sale it?

Patient

Payor

Clear product / service definition

Clear revenue model

Confidential 10

2. Relevant

Market

Customers

Current competition

Patient type/s

Big enough?

•Patient •Doc •Hospital •Payor

Needs

Severe enough?

Better enough?

Confidential 11

3. Unique

Needs Better enough?

Capable enough?

Early enough? Future competition

Same technology

Other technologies

Product S&W

Organization S&W

Time to market

Confidential 12

4. Protectable

Is it Patentable?

Enough Patent life?

Protect

License / sell Patent/s

Know-how

Protected Diclosed Clock starts ticking

Able to be copied Undisclosed Clock stopped

“As late as possible, but as soon as necessary…”

Confidential 13

5. Achievable

What must you prove?

What have you proved?

Target Product Profile

Route Map Validation

Risks and barriers

Confidential 14

5. Achievable

What must you prove?

What have you proved?

INTE

RN

AL

Market adoption

Price, reimbursement, access

Freedom To Operate

Clinical development

Supply Chain

CMC

Pre-clinical development

Scientific assessment

EXTE

RN

AL Potential buyers

Deal value

Deal timing (when)

Regulatory

Risks and barriers

Confidential 15

5. Achievable

What must you prove?

What have you proved?

”Licensable”?

How solid is what you proved?

Probability of success?

Reasonable timing?

Reasonable investment?

Risk mitigation?

TEAM

Confidential 16

6. Profitable

Decision tree

Cash flows

•Target Product Profile •Environment •Probabilized

•Probabilized nodes through the Route map.

Commercial scenarios

•For each scenario

Profitable enough?

Early enough?

5-10x

3-6 yrs

Likely enough? Higher than average.

Confidential 17

6. Profitable

Example: Decision Tree

Valuation was poor:

3x 9 yrs to exit

Summary

Confidential 19

Summary

TEAM

FINANCING

EXIT

PRODUCT / TECHNOLOGY

Resumen

With science, don’t gamble.

Thanks!

www.dynomicsbmt.com

Now follow us at: